

2° SA - APC
biotin conjugated Anti - his tag MAb
CD100 his
Anti - CD100 MAb
Plexin B1
293/Plexin
2° SA - APC
biotin conjugated
Anti - his tag MAb
CD100 his
Plexin B1

FIG. 1



Rb anti-his + sAPC
muCD100 only
0.625 ug/ml MAb
0.156 ug/ml MAb
MAb 67
mIgG isotype
MAb 76
Events
128
0
FL4-H
10^0
10^1
10^2
10^3
10^4

FIG. 2



67-2
76-1
Isotype Control
A570 (crystal violet)
2.5
2
1.5
1
0.5
0
0
20
40
60
ug/ml antibody

FIG. 3



2.5
2
1.5
1
0.5
0
Clinical Score
10
15
20
25
30
35
40
45
50
Days post EAE Induction
Mouse IgG
MAb 76 1X/Week
MAb 67 1X/Week
MAb 76 2X/Week
MAb 67 2X/Week

FIG. 4A



80
70
60
50
40
30
20
10
0
Percent Inhibition of GMS
MAb 76 1X/Week
MAb 67 1X/Week
MAb 76 2X/Week
MAb 67 2X/Week
Treatment

FIG. 4B



Mean Clinical EAE Score
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50
Day post EAE induction
Mouse IgG
MAb 67
MAb 76

FIG. 5A



Percent Reduction in GMS
80
70
60
50
40
30
20
10
0
MAb 67
MAb 76
Treatment

FIG. 5B



EAE clinical score
clinical score
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0
5
10
15
20
25
30
35
40
45
50
55
60
Days post immunization
control IgG
MAb 67

FIG. 6



100
80
60
40
20
0
-20
% Blocking
0.01
0.1
1
10
100
nM blocking antibody
67
Human IgG4
2503

FIG. 7A



70
60
50
40
30
20
10
0
-10
% Blocking
0.01
0.1
1
10
100
nM blocking antibody
67
Human IgG4
2503

FIG. 7B



sAPC only
huCD100
1.0 ug isotype
1.0 ug MAb
67
2503
Events
128
0
FL4-H
10^0
10^1
10^2
10^3
10^4

FIG. 8A



sAPC only
marmCD100
1.0 ug isotype
1.0 ug MAb
67
2503
Events
128
0
FL4-H
10^0
10^1
10^2
10^3
10^4

FIG. 8B



sAPC only
mouseCD100
1.0 ug isotype
1.0 ug MAb
67
2503
Events
128
0
FL4-H
10^0
10^1
10^2
10^3
10^4

FIG. 8C



A570 (crystal violet)
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
12.5
6.25
3.125
1.5625
0.7815
ug/ml blocking ab
mab67
MAb 2503
IgG4

FIG. 9A



A570 (crystal violet)
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
12.5
6.25
3.125
1.5625
0.7815
ug/ml blocking ab
mab67
MAb 2503
IgG4

FIG. 9B



Tumor Volume (mm³)
1400
1200
1000
800
600
400
200
0
5
7
9
11
13
15
17
19
Day
wt Bab
CD170 KO

FIG. 10



Mean Leg Volume (mm³)
2500
2000
1500
1000
500
0
6
8
10
12
14
16
18
20
22
24
days post graft
MOUSE IgG
MAb 67
KO

FIG. 11



ARTHRITIS INDUCTION
ARTHRITIS DEVELOPMENT
WK-1
WK-2
WK-3
WK-4
WK-5
WK-6
Day 0- Immunisation by:
Intradermal injection (tail) of an emulsion comprising collagen /CFA emulsion.
Test and control items
Test item/negative control administered once daily from day.
Intraperitoneal collagen challenge
Collagen in PBS on Day 21.

FIG. 12




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B



1000
Endpoint
600
400
200
0
0
10
20
30
40
50
Days post graft
Control IgG
MAb 67

FIG. 15




FIG. 16A




FIG. 16B



1500
1000
500
0
Tumor Volume (mm3)
0
5
10
15
Days post graft
BALB/c WT
BALB/c SEMA4D -/-

FIG. 17



Tumor Volume (cm3)
3
2
1
0
0
5
10
15
20
25
Days post Graft
Control IgG4
MAb 2503

FIG. 18




FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B



Cynomolgus (male and female combined)
Average SEMA4d Saturation
Percent Saturation
120
100
80
60
40
20
0
0
20
40
60
Days
0 mg/kg
0.01 mg/kg
0.1 mg/kg
1 mg/kg
10 mg/kg
100 mg/kg

FIG. 21